Valuation: AC Immune SA

Market Cap 217M 262M 232M 198M 373M 25.19B 378M 2.63B 1.02B 12.83B 982M 961M 41.21B P/E 2026 *
-5.28x
P/E 2027 * 11.3x
Enterprise Value 173M 208M 185M 157M 296M 20B 300M 2.09B 808M 10.19B 780M 763M 32.72B EV / Sales 2026 *
9.24x
EV / Sales 2027 * 2.63x
Free-Float
56.14%
Yield 2026 *
-
Yield 2027 * -
1 day+7.25%
1 week+5.64%
Current month+7.25%
1 month+4.85%
3 months+18.07%
6 months+0.72%
Current year-10.51%
1 week 2.4
Extreme 2.405
2.84
1 month 2.4
Extreme 2.405
3
Current year 2.1
Extreme 2.095
3.9
1 year 2.1
Extreme 2.095
4
3 years 1.43
Extreme 1.4299
5.14
5 years 1.43
Extreme 1.4299
8.14
10 years 1.43
Extreme 1.4299
18.95
Manager TitleAgeSince
Chief Executive Officer 64 10/06/2026
Director of Finance/CFO 37 31/12/2021
Chief Tech/Sci/R&D Officer 45 31/12/2012
Director TitleAgeSince
Director/Board Member 70 31/12/2018
Director/Board Member 72 19/11/2020
Director/Board Member 65 28/10/2021
Date Insider Type Main position Quantity % Market Cap. Importance
15/05/26 Sell

Founder

-10,000 0.0098%
15/04/26 Sell

Founder

10,000 0.0101%
20/03/26 Other

Chief Operating Officer

520,081 0.5256%
Change 5-day change 1-year change 3-year change Capi.($)
+7.25%+5.64%-7.57%-1.06% 260M
-0.62%-2.71%+39.30%+113.61% 1,031B
-2.30%-4.44%+39.03%+66.72% 638B
-0.63%-1.96%+6.36%+75.33% 462B
-1.03%-2.82%+59.56%+40.23% 359B
-0.03%-3.91%+34.28%+39.35% 335B
-1.58%+0.39%+17.92%+25.77% 273B
-2.02%-3.20%+7.60%+8.38% 253B
-3.38%+0.30%+36.44%+52.93% 228B
-1.04%-1.46%+32.70%+99.06% 185B
Average -0.32%-1.07%+26.56%+52.03% 376.41B
Weighted average by Cap. -0.89%-0.35%+32.51%+69.52%

Financials

2026 *2027 *
Net sales 18.66M 22.47M 19.96M 17.01M 32.02M 2.16B 32.46M 226M 87.41M 1.1B 84.37M 82.54M 3.54B 89.19M 107M 95.37M 81.28M 153M 10.34B 155M 1.08B 418M 5.27B 403M 394M 16.91B
Net income -42.87M -51.62M -45.84M -39.07M -73.55M -4.97B -74.56M -519M -201M -2.53B -194M -190M -8.13B 19.95M 24.02M 21.34M 18.18M 34.23M 2.31B 34.7M 241M 93.45M 1.18B 90.2M 88.24M 3.78B
Net Debt -44.8M -53.94M -47.91M -40.82M -76.86M -5.19B -77.92M -542M -210M -2.64B -203M -198M -8.49B 17.1M 20.59M 18.29M 15.58M 29.34M 1.98B 29.74M 207M 80.08M 1.01B 77.29M 75.62M 3.24B
Logo AC Immune SA
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Employees
106
Date Price Change Volume
01/10/26 US$2.810 +7.25% 352,695
30/09/26 US$2.620 +0.77% 199,646
29/09/26 US$2.600 -0.38% 139,228
28/09/26 US$2.610 +3.57% 189,115
25/09/26 US$2.520 -5.26% 323,580
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.186CHF
Average target price
7.095CHF
Spread / Average Target
+224.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACIU Stock